Contact Us

No Form
*    Denotes required field.

   * First Name 

   * Last Name 

   * Email 

Phone 

Cell Phone 

Street Address 

Zip Code 

City 

State 

   * Please describe your case:

Date of Incident : 

For verification purposes, please answer the below question:
+
=

No Yes, I agree to the Parker Waichman LLP disclaimers. Click here to review.

Yes, I would like to receive the Parker Waichman LLP monthly newsletter, InjuryAlert.

please do not fill out the field below.

Tasmar

WE ARE PRESENTLY NOT TAKING ANY MORE CASES.
WE ARE PRESENTLY NOT TAKING ANY MORE CASES.

Tasmar Side Effects May Lead To Stroke Lawsuits

Tasmar | Lawsuits, Lawyers | Side Effects: Stroke, Pulmonary Embolism, Blood Clots, Uterus Cancer

Tasmar, also known as tolcapone, is a C.O.M.T. inhibitor and is used to treat symptoms associated with Parkinson's disease. Tasmar is often used in combination with other Parkinson medications such as levodopa and carbidopa. First approved in January 1998, about ten months on the market Tasmar warnings were issued and a boxed warning was added to Tasmar product labeling. Physicians prescribing Tasmar was advised about reports of a new finding of fatal liver injury associated with the use of Tasmar.

In 1998 Roche issued a warning letter to doctors informing them of the increased risk of liver problems in patients taking Tasmar. The letter suggests that doctors only give Tasmar to those patients who do not respond to other similar medications.

The drug has caused fatal liver failure in at least three people. The more than 60,000 people who have taken Tasmar may be 100 times more likely to develop liver problems than those who have not taken the drug. Roche refers to the liver damage caused by Tasmar as a "hepatocellular injury.

The adverse Tasmar effects led the manufacturer and the FDA to recommend significant changes in how Tasmar is used, reserved only for patients who do not have severe movement abnormalities and who do not respond to or who are not appropriate candidates for alternate treatments. Patients were advised to self-monitor themselves while on Tasmar for signs of liver disease, including jaundice, fatigue, and loss of appetite. In addition, patients that fail to show a substantial clinical benefit in the initial three weeks of Tasmar treatment were advised to be withdrawn from the drug.

Legal Help For Victims Affected By Tasmar

If you or a loved one were affected by Tasmar, please fill out the form at the right for a free case evaluation by a qualified attorney or call us anytime at 1-800-YOURLAWYER (1-800-968-7529).



 

TasmarRSS Feed

NEW WARNINGS FOR PARKINSON'S DRUG, TASMAR

Nov 16, 1998 | www.fda.gov
FDA and Hoffmann-La Roche Inc., the manufacturer of the drug Tasmar for patients with Parkinson's Disease, are advising doctors about reports of a new finding of fatal liver injury associated with use of the drug, and recommending significant changes in how it is used. Because of these reports, Tasmar's labeling now states that the drug should be reserved for use only in patients who do not have severe movement abnormalities and who don't respond to or who are not appropriate candidates for...

More Tasmar News

Parker Waichman Accolades And Reviews Best Lawyers Find Us On Avvo